Phase 2 Trial of Single Agent Ifosfamide/Mesna in Patients with Platinum/Paclitaxel Refractory Ovarian Cancer Who Have Not Previously Been Treated with an Alkylating Agent

By Markman M.   Kennedy A.   Sutton G.   Hurteau J.   Webster K.   Peterson G.   Kulp B.   Belinson J.  

Gynecologic Oncology, Vol. 70, Iss. 2, 1998-08 ,pp. : 272-274

Elsevier

Access to resources Recommend Favorite

Salvage chemotherapy with docetaxel and pegylated liposomal doxorubicin in pretreated patients with platinum- and taxane-sensitive ovarian cancer: a multicenter phase II trial of the Hellenic Oncology Research Group (HORG)

By Koinis Filippos   Polyzos Aristidis   Christopoulou Athina   Zafeiriou Zafeiris   Emmanouilidis Christos   Papadimitraki Elisavet   Kalykaki Antonia   Kalbakis Kostas   Samonis George   Georgoulias Vassilis  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 4, 2014-04 ,pp. : 819-825

Springer Publishing Company

Access to resources Recommend Favorite

Feasibility study of oral cyclophosphamide salvage therapy for the treatment of heavily pretreated patients with recurrent epithelial ovarian cancer

By Watanabe Yoh   Etoh Tomomaro   Koike Eiji   Mizuno Yoshiaki   Wang Wei-Min   Hoshiai Hiroshi  

International Journal of Clinical Oncology, Vol. 15, Iss. 5, 2010-10 ,pp. : 468-471

Springer Publishing Company

Access to resources Recommend Favorite

A Phase II Study of Paclitaxel in Platinum Pretreated Ovarian Cancer. A Hellenic Cooperative Oncology Group Study

By Aravantinos G.   Skarlos D.V.   Kosmidis P.   Athanassiades A.   Bafaloukos D.   Giannakakis T.   Karpathios S.   Fountzilas G.  

European Journal of Cancer, Vol. 33, Iss. 1, 1997-01 ,pp. : 160-163

Elsevier

Access to resources Recommend Favorite

Salvage Therapy with Capecitabine Plus Weekly Paclitaxel in Heavily Pretreated Advanced Breast Cancer: A Multicenter Phase II Study

By Bari Mario  

American Journal of Cancer, Vol. 4, Iss. 5, 2005-01 ,pp. : 307-313

Adis International

Access to resources Recommend Favorite